Spero Therapeutics Announces First Patient, First Visit for

$95 million in development milestones payable over two years, as part of GSK license agreement...

Related Keywords

Japan , Massachusetts , United States , Cambridge , Cambridgeshire , United Kingdom , Lora Grassilli , Sath Shukla , Ted Jenkins , Tebipenem Hbr Research , Us Department Of Health , Exchange Commission , Health Media Relations , Zeno Group , Biomedical Advanced Research , Meiji Seika Pharma Co , Administration For Strategic Preparedness , Development Authority , Spero Therapeutics Inc , Drug Administration , Human Services , Nasdaq , Meiji Seika Pharma , Qualified Infectious Disease Product , Fast Track , Strategic Preparedness , Relations Contact , Investor Relations , Health Media , Nasdaq Spro , Spero Therapeutics , Nc ,